MediWound to Report Second Quarter 2024 Financial Results
MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced it will release its Q2 2024 financial results on August 14, 2024. The company will host a conference call and webcast at 8:30 am Eastern Time on the same day to discuss the results and provide corporate updates.
Investors and interested parties can join the call using the following details:
- Toll-Free: 1-833-630-1956
- Israel: 1-80-921-2373
- International: 1-412-317-1837
MediWound (Nasdaq: MDWD), un leader nella terapia enzimatica per la riparazione dei tessuti, ha annunciato che rilascerà i suoi risultati finanziari del Q2 2024 il 14 agosto 2024. L'azienda ospiterà una conference call e una diretta web alle 8:30 ora orientale nello stesso giorno per discutere i risultati e fornire aggiornamenti aziendali.
Gli investitori e le parti interessate possono unirsi alla chiamata utilizzando i seguenti dettagli:
- Numero Verde: 1-833-630-1956
- Israele: 1-80-921-2373
- Internazionale: 1-412-317-1837
MediWound (Nasdaq: MDWD), un líder en terapias enzimáticas para la reparación de tejidos, ha anunciado que publicará sus resultados financieros del Q2 2024 el 14 de agosto de 2024. La compañía organizará una llamada de conferencia y transmisión web a las 8:30 am hora del Este el mismo día para discutir los resultados y proporcionar actualizaciones corporativas.
Los inversionistas y partes interesadas pueden unirse a la llamada utilizando los siguientes detalles:
- Llamada gratuita: 1-833-630-1956
- Israel: 1-80-921-2373
- Internacional: 1-412-317-1837
MediWound (Nasdaq: MDWD), 조직 복구를 위한 효소 치료의 선두주자로, 2024년 2분기 재무 결과를 2024년 8월 14일에 발표할 예정이라고 발표했습니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 주최합니다.
투자자 및 관심 있는 분들은 다음 세부 정보를 이용하여 전화에 참여할 수 있습니다:
- 무료 전화: 1-833-630-1956
- 이스라엘: 1-80-921-2373
- 국제: 1-412-317-1837
MediWound (Nasdaq: MDWD), un leader dans les thérapies enzymatiques pour la réparation des tissus, a annoncé qu'il publiera ses résultats financiers du T2 2024 le 14 août 2024. La société organisera une conférence téléphonique et un webinaire le même jour à 8h30, heure de l'Est, pour discuter des résultats et fournir des mises à jour sur l'entreprise.
Les investisseurs et les parties intéressées peuvent rejoindre l'appel en utilisant les détails suivants :
- Numéro sans frais : 1-833-630-1956
- Israël : 1-80-921-2373
- International : 1-412-317-1837
MediWound (Nasdaq: MDWD), ein führendes Unternehmen in der enzymatischen Therapie zur Gewebereparatur, hat angekündigt, dass es seine Finanzergebnisse für Q2 2024 am 14. August 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und Unternehmensupdates zu geben.
Investoren und interessierte Parteien können sich mit den folgenden Einzelheiten in die Konferenz einwählen:
- Gebührenfrei: 1-833-630-1956
- Israel: 1-80-921-2373
- International: 1-412-317-1837
- None.
- None.
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time
YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the second quarter ended June 30, 2024 on Wednesday, August 14, 2024.
Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions.
Dial-in and call details are as follows:
| Conference Call & Webcast Details | |
| Toll-Free: | 1-833-630-1956 |
| Israel: | 1-80-921-2373 |
| International: | 1-412-317-1837 |
| Webcast: | Click HERE |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid®, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline, including the company’s lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for the debridement of chronic wounds, offering significant potential advantages over the dominant
For more information visit www.mediwound.com and follow the Company on LinkedIn.
| MediWound Contacts: | |
| Hani Luxenburg | Daniel Ferry |
| Chief Financial Officer | Managing Director |
| MediWound Ltd. | LifeSci Advisors, LLC |
| ir@mediwound.com | daniel@lifesciadvisors.com |
| Media Contact: | |
| Ellie Hanson | |
| FINN Partners for MediWound | |
| ellie.hanson@finnpartners.com | |
| 929-588-2008 | |
FAQ
When will MediWound (MDWD) release its Q2 2024 financial results?
What time is MediWound's (MDWD) Q2 2024 earnings call scheduled for?
How can investors join MediWound's (MDWD) Q2 2024 earnings call?
Will there be a replay available for MediWound's (MDWD) Q2 2024 earnings call?
